XOMA Corporation
XOMAXOMA is a royalty aggregator that provides non-dilutive, non-recourse capital to biotechnology companies in exchange for economic rights to future milestone and royalty payments.
Earnings
Next report
Aug 12, 2026 (in a month)Financials
Q1 2026Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
Profile
XOMA is a royalty aggregator that provides non-dilutive, non-recourse capital to biotechnology companies in exchange for economic rights to future milestone and royalty payments. The company focuses on building a diversified portfolio of clinical and commercial-stage assets to mitigate single-asset binary risk while maintaining a lean, capital-efficient corporate structure. By acquiring interests in programs where R&D and commercialization costs are borne by third-party sponsors, XOMA generates value through long-term cash receipts from drug development successes.
XOMA operates as a specialized aggregator focusing on early-to-mid-stage clinical assets, differentiating itself through structured acquisitions of entire biotech entities to secure royalty streams.
Questions, answered.
- What is XOMA Corporation's market cap?
- XOMA Corporation (XOMA) has a market capitalization of $792.0M and trades on NASDAQ.
- What is XOMA Corporation's revenue and profitability?
- XOMA Corporation generated $48.6M in trailing twelve-month revenue with net income of $33.8M, representing a net margin of 69.6%. These figures are based on the Q1 2026 filing.
- Who are XOMA Corporation's competitors?
- XOMA Corporation's key competitors include Ligand Pharmaceuticals, Royalty Pharma, TherapeuticsMD, Inc., and others. These companies compete in similar markets and product categories.
- Who does XOMA Corporation partner with?
- XOMA Corporation's notable partners include Roche, UCB, Heron Therapeutics.
- What subsidiaries does XOMA Corporation have?
- XOMA Corporation's subsidiaries include Kinnate Biopharma.
- Where is XOMA Corporation headquartered?
- XOMA Corporation is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 1986.
